Daniela Pugliese, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi Inflammatory Bowel Disease Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy Abstract: Significant advances in the management of patients with ulcerative colitis (UC) have been made since the introduction of anti-tumor necrosis factor (TNF)-alpha agents, especially for those who fail or do not tolerate conventional therapies.Two drugs, infliximab first, then adalimumab Extend Shipping Contract afterward, showed effectiveness in inducing and maintaining long-term remission both in pivotal trials as well as in clinical practice.However, approximately 25% of patients with UC, who fail or do not tolerate all available therapies, require a colectomy for refractory disease.The therapeutic scenario of UC has been recently upgraded by the introduction of golimumab, the latest anti TNF-alpha agent to be approved.Golimumab is a totally humanized monoclonal antibody, administered by a subcutaneous injection every 4 weeks.
Treatment with golimumab has shown to be effective to induce sustained clinical benefit in tough-to-treat patients with UC, including steroid and/or immunosuppressive refractory and steroid-dependent patients.In this Toddler review, we summarize all available efficacy and safety data of golimumab in UC, analyzing the potential therapeutic position for the treatment of refractory patients with UC.Keywords: ulcerative colitis, refractoriness, anti-TNF-alpha, golimumab .